ライフサイエンスコーパス: corneal graft rejection

1 ive and prognostic role of 3D En/DMT maps in corneal graft rejection.

2 esis is associated with an increased rate of corneal graft rejection.

3 r postoperative management and prevention of corneal graft rejection.

4 ng IL-17A at this time significantly reduced corneal graft rejection.

5 s demonstrated to be markedly upregulated in corneal graft rejection.

6 mmune responses and reduces the incidence of corneal graft rejection.

7 contribution of donor-specific antibodies to corneal graft rejection.

8 s into the cornea with the aim of preventing corneal graft rejection.

9 or is administered after surgery, to prevent corneal graft rejection.

10 othesis that CTLs are essential in promoting corneal graft rejection.

11 associated with CD8(+) T cells, in promoting corneal graft rejection.

12 e as effective as viable cells in preventing corneal graft rejection.

13 correlated to clinical signs and symptoms of corneal graft rejection.

14 is the mainstay for preventing and treating corneal graft rejection.

15 e presence of clinical signs and symptoms of corneal graft rejection.

16 tive tool in the diagnosis and management of corneal graft rejection.

17 omplex (En/DM) characteristics in diagnosing corneal graft rejection.

18 with penetrating keratoplasty (15 eyes with corneal graft rejection, 23 eyes without rejection) and

19 les, saline, or DSP in solution demonstrated corneal graft rejection accompanied by severe corneal ed

20 uggested a role for Fas-induced apoptosis in corneal graft rejection, additional experiments indicate

21 ickness (En/DMT) are of predictive value for corneal graft rejection after high-risk corneal transpla

22 ncompatibility (including H-Y mismatches) on corneal graft rejection and failure was evaluated using

23 that CD8(+) CTLs are essential in promoting corneal graft rejection and instead further implicates d

24 tion of allospecific effector macrophages in corneal graft rejection and the role of CD4(+) T cells a

25 y selected controls who did not experience a corneal graft rejection at their matched cases' index da

26 icroscopy (IVCM) can aid in the diagnosis of corneal graft rejection by detecting cellular corneal ch

27 Assessment of patients with corneal graft rejection by IVCM may serve as an adjuncti

28 Alloantibody, although not necessary for corneal graft rejection, can produce extensive injury to

29 Patients with corneal graft rejection demonstrate a significant increa

30 tained release of corticosteroids to prevent corneal graft rejection following subconjunctival inject

31 ng sixty eyes (60 patients) at high risk for corneal graft rejection (GR) because of previous immunol

32 unct to prevent graft neovascularization and corneal graft rejection in high-risk corneal transplants

33 Corneal graft rejection in IFN-gamma-deficient hosts was

34 ed further the role of the DLN and spleen in corneal graft rejection in mice.

35 Thus, MHC matching may reduce the risk of corneal graft rejection in patients with atopic keratoco

36 study is to develop a pre-clinical model of corneal graft rejection in the semi-inbred NIH minipig a

37 Thus, allergy-induced exacerbation of corneal graft rejection is due to the production of IL-4

38 eye, so the required frequency of dosing for corneal graft rejection management can be as high as onc

39 rts have documented uveitis flares and acute corneal graft rejection occurring within the first 3 wee

40 se of corticosteroids may reduce the rate of corneal graft rejection, perhaps especially in the days

41 The B6 corneal graft rejection rate in BALB/c vs Jalpha281 knoc

42 HC matching dramatically reduces the risk of corneal graft rejection when IFN-gamma is depressed or a

43 ., the SM node, is the major DLN involved in corneal graft rejection whereas its nearest neighbor, th

44 3D En/DMT maps can diagnose active corneal graft rejection with excellent accuracy, sensiti

45 approach for safely preventing and treating corneal graft rejection with the potential for improved